ログイン
Language:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. C. 医薬保健学域; 医学類・薬学類・医薬科学類・保健学類
  2. c 20. 紀要
  3. Journal of wellness and health care
  4. Vol.44 No.1 (2020)

The effect of direct oral anticoagulants on blood protein C activity

https://doi.org/10.24517/00059313
https://doi.org/10.24517/00059313
e8f371ae-fca7-4a4f-9eac-ed436135553b
名前 / ファイル ライセンス アクション
2434-1509-44-1_33-41.pdf 2434-1509-44-1_33-41 (1.6 MB)
license.icon
アイテムタイプ 紀要論文 / Departmental Bulletin Paper(1)
公開日 2020-09-03
タイトル
タイトル The effect of direct oral anticoagulants on blood protein C activity
タイトル
タイトル The effect of direct oral anticoagulants on blood protein C activity
言語 en
言語
言語 eng
キーワード
言語 en
主題Scheme Other
主題 direct oral anticoagulant
キーワード
言語 en
主題Scheme Other
主題 protein C
キーワード
言語 en
主題Scheme Other
主題 clotting assay
キーワード
言語 en
主題Scheme Other
主題 chromogenic assay
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ departmental bulletin paper
ID登録
ID登録 10.24517/00059313
ID登録タイプ JaLC
著者 Terakami, Takako

× Terakami, Takako

WEKO 94142

Terakami, Takako

Search repository
Sekiya, Akiko

× Sekiya, Akiko

WEKO 86556
e-Rad 10452111

Sekiya, Akiko

Search repository
Hayashi, Kenshi

× Hayashi, Kenshi

WEKO 89042
e-Rad 00422642

Hayashi, Kenshi

Search repository
Suzuki, Takeshi

× Suzuki, Takeshi

WEKO 94546

Suzuki, Takeshi

Search repository
Furusho, Hiroshi

× Furusho, Hiroshi

WEKO 94547

Furusho, Hiroshi

Search repository
Asakura, Hidesaku

× Asakura, Hidesaku

WEKO 85793
e-Rad 60192936

Asakura, Hidesaku

Search repository
Morishita, Eriko

× Morishita, Eriko

WEKO 77302
e-Rad 50251921

Morishita, Eriko

Search repository
Wada, Takashi

× Wada, Takashi

WEKO 70236
e-Rad 40334784

Wada, Takashi

Search repository
著者別表示 寺上, 貴子

× 寺上, 貴子

WEKO 94142

寺上, 貴子

Search repository
關谷, 暁子

× 關谷, 暁子

WEKO 94548

關谷, 暁子

Search repository
林, 研至

× 林, 研至

WEKO 266
e-Rad 00422642
金沢大学研究者情報 00422642
研究者番号 00422642

林, 研至

Search repository
鈴木, 健史

× 鈴木, 健史

WEKO 94549

鈴木, 健史

Search repository
古荘, 浩司

× 古荘, 浩司

WEKO 94550

古荘, 浩司

Search repository
朝倉, 英策

× 朝倉, 英策

WEKO 260
e-Rad 60192936
金沢大学研究者情報 60192936
研究者番号 60192936

朝倉, 英策

Search repository
森下, 英理子

× 森下, 英理子

WEKO 287
e-Rad 50251921
金沢大学研究者情報 50251921
研究者番号 50251921

森下, 英理子

Search repository
和田, 隆志

× 和田, 隆志

WEKO 118
e-Rad 40334784
金沢大学研究者情報 40334784
研究者番号 40334784

和田, 隆志

Search repository
書誌情報 Journal of wellness and health care
en : Journal of wellness and health care

巻 44, 号 1, p. 33-41, 発行日 2020-08-03
ISSN
収録物識別子タイプ ISSN
収録物識別子 2434-1509
出版者
出版者 Wellness and Health Care Society
出版者(別名)
出版者 ウェルネス・ヘルスケア学会
抄録
内容記述タイプ Abstract
内容記述 [Aim] In this study, the effect of direct oral anticoagulants (DOACs) on protein C (PC) activity was examined using several measuring reagents.
[Materials and Methods] In total, 90 patients (60 male and 30 female) with nonvalvular atrial fibrillation or venous thromboembolism (VTE) who were on anticoagulation therapy with DOACs (rivaroxaban, apixaban, or edoxaban) were studied. The plasma levels of PC activity were measured by means of a clotting assay and chromogenic substrate assay, using three reagents for each type of assay.
[Result] Prothrombin time (PT) and activated partial thromboplastin time (APTT) were significantly prolonged in a dose-dependent manner in patients who were taking rivaroxaban or edoxaban. PC activity, as measured by all three reagents using the clotting assay, was influenced only by rivaroxaban, indicating an increase in PC activity in a dose-dependent manner. Apixaban did not have any influence on the measurements made using all three reagents in the clotting assay. On the other hand, none of the three FXa inhibitors had any influence on PC activity when it was measured using the three reagents in the chromogenic substrate assay. Plasma samples were collected before, as well as two and four to eight weeks after rivaroxaban administration in seven patients with AF or VTE sequentially. In all three regents using the clotting assay, plasma levels of PC activity had increased after the administration of rivaroxaban. On the other hand, all three regents using the chromogenic assay had very little influence on PC activity after the administration of rivaroxaban.
[Conclusion] The inhibitory effects of the different types of DOACs on clotting activity interfere with clotting test measurement systems in patients receiving DOAC therapy. When measuring PC activity while the patient is taking rivaroxaban or edoxaban, it is necessary to use the chromogenic substrate assay to avoid false highs. Moreover, collecting specimens when blood levels of drugs are low, e.g. during the trough phase, whenever possible, would be one way to minimize interference.
著者版フラグ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
見出し
大見出し 原著
言語 ja
見出し
大見出し Original Article
言語 en
戻る
0
views
See details
Views

Versions

Ver.1 2023-07-27 15:36:47.221695
Show All versions

Share

Share
tweet

Cite as

Other

print

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX
  • ZIP

コミュニティ

確認

確認

確認


Powered by WEKO3


Powered by WEKO3